The PACAP receptor: a novel target for migraine treatment

Forskning

The PACAP receptor: a novel target for migraine treatment

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The PACAP receptor: a novel target for migraine treatment. / Schytz, Henrik W; Olesen, Jes; Ashina, Messoud.

I: Neurotherapeutics, Bind 7, Nr. 2, 01.04.2010, s. 191-6.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Schytz, HW, Olesen, J & Ashina, M 2010, 'The PACAP receptor: a novel target for migraine treatment', Neurotherapeutics, bind 7, nr. 2, s. 191-6. https://doi.org/10.1016/j.nurt.2010.02.003

APA

Schytz, H. W., Olesen, J., & Ashina, M. (2010). The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics, 7(2), 191-6. https://doi.org/10.1016/j.nurt.2010.02.003

Vancouver

Schytz HW, Olesen J, Ashina M. The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics. 2010 apr. 1;7(2):191-6. https://doi.org/10.1016/j.nurt.2010.02.003

Author

Schytz, Henrik W ; Olesen, Jes ; Ashina, Messoud. / The PACAP receptor: a novel target for migraine treatment. I: Neurotherapeutics. 2010 ; Bind 7, Nr. 2. s. 191-6.

Bibtex

@article{0497d125f8834c15a8cb53b2be8f11e6,

title = "The PACAP receptor: a novel target for migraine treatment",

abstract = "The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.",

author = "Schytz, {Henrik W} and Jes Olesen and Messoud Ashina",

year = "2010",

month = apr,

day = "1",

doi = "http://dx.doi.org/10.1016/j.nurt.2010.02.003",

language = "English",

volume = "7",

pages = "191--6",

journal = "Neurotherapeutics",

issn = "1933-7213",

publisher = "Springer",

number = "2",

}

RIS

TY - JOUR

T1 - The PACAP receptor: a novel target for migraine treatment

AU - Schytz, Henrik W

AU - Olesen, Jes

AU - Ashina, Messoud

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.

AB - The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.

U2 - http://dx.doi.org/10.1016/j.nurt.2010.02.003

DO - http://dx.doi.org/10.1016/j.nurt.2010.02.003

M3 - Journal article

VL - 7

SP - 191

EP - 196

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 2

ER -

ID: 34093581